Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma

BACKGROUND AND AIM: Currently, there is no molecular‐targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u‐HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real‐world study, we aimed to investigate the therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomonari, Tetsu, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Sogabe, Msasahiro, Okamoto, Koichi, Miyamoto, Hiroshi, Muguruma, Naoki, Takayama, Tetsuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731817/
https://www.ncbi.nlm.nih.gov/pubmed/33319048
http://dx.doi.org/10.1002/jgh3.12408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731817/
https://www.ncbi.nlm.nih.gov/pubmed/33319048
http://dx.doi.org/10.1002/jgh3.12408

Ejemplares similares